Diabetes Management Gel
Type 2 Diabetes
Formulation DevelopmentActive
Key Facts
About Gelteq Limited
Gelteq Limited's mission is to revolutionize oral delivery by deploying its patented gel platform, which enhances solubility, absorption, and patient experience for pharmaceuticals and nutrients. Its key achievement is the development of a versatile, stable gel matrix in collaboration with Monash University, ranked #1 globally in pharmaceutical science. The company's strategy is to generate value through partnerships, licensing its technology, and co-developing products across healthcare, nutrition, and animal health sectors, without bearing the full cost of drug discovery.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| V-Go | MannKind | Approved |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |
| Undisclosed (Targeting IAPP) | Pangolin Therapeutics | Pre-clinical |